
Neurogene is focused on developing life-changing genetic medicines for patients and families affected by rare, devastating neurological diseases.
Neurogene revenue
Neurogene has not published its revenue, and GetLatka has no sourced estimate yet. Know the figure? Send us a source.
Neurogene market cap
Neurogene is a public company. Its market capitalisation was $569.9M in September 2026.
Neurogene CEO
Rachel McMinn is CEO of Neurogene.
Neurogene FAQ
Is Neurogene publicly traded?
Yes. Neurogene is a public company, with a market capitalisation of $569.9M in September 2026.
Who is the CEO of Neurogene?
Rachel McMinn is the CEO of Neurogene.
Categories
How this page is sourced
Founder figures link to the second they were said; public figures name their source; estimates are marked EST and say whose they are. Not financial advice.
Updated Sep 28, 2026Data disclaimerReport a correctionClaim this profileRun Neurogene? Join the podcast